Magnitude of Non-Alcoholic Fatty Liver Disease: Western Perspective

Publication date: Available online 16 May 2019Source: Journal of Clinical and Experimental HepatologyAuthor(s): Naga Swetha Samji, Rajanshu Verma, Sanjaya K. SatapathyAbstractThe incidence of NAFLD is continuing to rise worldwide and it is estimated that this disquieting trend will continue for another 10-15 years before prevalence begins to decrease. NAFLD is the hepatic manifestation of metabolic syndrome. As obesity, diabetes and other life style related diseases continue to rise, the spectrum of NAFLD e.g., NASH (nonalcoholic steatohepatitis), liver fibrosis, liver cirrhosis, liver related morbidity and mortality will increase in parallel. Its widespread prevalence and associated economic burden have drawn significant attention and a multitude of pharmaceutical companies are participating in active research trying to find a “cure”. Unfortunately, as of now, no targeted treatment exists to treat this condition and so emphasis has been on its prevention. The current review focuses on the epidemiology, clinical characteristics, risk factors, and clinical outcomes of NAFLD in Western countries. It is important to understand the magnitude of NAFLD and its risk factors in Western Countries where the prevalence of NAFLD has now reached epidemic proportions to identify the best strategy to prevent and possibly control this epidemic.
Source: Journal of Clinical and Experimental Hepatology - Category: Gastroenterology Source Type: research

Related Links:

Ali Mahzari1, Songpei Li1, Xiu Zhou1,2, Dongli Li2, Sherouk Fouda1, Majid Alhomrani1, Wala Alzahrani1, Stephen R. Robinson1 and Ji-Ming Ye1,2* 1Lipid Biology and Metabolic Disease Laboratory, School of Health and Biomedical Sciences, RMIT University, Melbourne, VIC, Australia 2School of Biotechnology and Health Sciences, Wuyi University, Jiangmen, China The present study investigated the effects of matrine on non-alcoholic steatohepatitis (NASH) in mice induced by a methionine choline-deficient (MCD) diet and the mechanism involved. The study was performed in C57B/6J mice fed a MCD diet for 6 weeks to induce NAS...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
The burden associated with non-alcoholic fatty liver disease (NAFLD) is becoming a major problem for health systems worldwide.1 As part of the metabolic syndrome, NAFLD prevalence is increasing in parallel with the epidemics of obesity and diabetes;2 although in most cases NAFLD remains a non-progressive disease, in some cases non-alcoholic steatohepatitis (NASH) and progressive fibrosis may occur, finally progressing to cirrhosis and hepatocellular carcinoma.3 Thus, the costs associated with liver disease of metabolic origin and its complications are likely to soon outweigh the costs of liver diseases of viral origin.
Source: Journal of Hepatology - Category: Gastroenterology Authors: Tags: Research Article Source Type: research
Abstract With the ever increasing global obesity pandemic, clinical burden from obesity related complications are anticipated in parallel. Bariatric surgery, a treatment approved for weight loss in morbidly obese patients, has reported to be associated with good outcomes, such as reversal of type two diabetes mellitus and reducing all-cause mortality on a long term basis. However, complications from bariatric surgery have similarly been reported. In particular, with the onslaught of non-alcoholic fatty liver disease (NAFLD) epidemic, in associated with obesity and metabolic syndrome, there is increasing prevalence...
Source: World Journal of Gastroenterology : WJG - Category: Gastroenterology Authors: Tags: World J Gastroenterol Source Type: research
Abstract Hepatocellular carcinoma is the third most frequent cause of cancer death worldwide, particularly in Asia and Africa. Most cases complicate an underlying liver cirrhosis due to hepatitis B or C chronic virus infection or alcoholic abuse. But, following the current epidemics of obesity and type 2 diabetes, it appears that these diseases, associated in metabolic syndrome, are responsible for non alcoholic fatty liver disease at risk of HCC frequently before the stage of cirrhosis. Recent hypotheses consider that in the near future, cancer deaths due to HCC will overpass in USA those due to breast or colorec...
Source: Bulletin du Cancer - Category: Cancer & Oncology Authors: Tags: Bull Cancer Source Type: research
Authors: Agustin S, Graupera I, Caballeria J, en nombre del grupo de trabajo sobre «Hígado graso no alcohólico» de la Societat Catalana de Digestologia Abstract Non-alcoholic fatty liver disease (NAFLD) consists of an excessive depositing of fat in the liver, which can end up by causing inflammation, fibrosis and also cirrhosis with the corresponding complications including liver cancer. NAFLD has become the most common liver disease worldwide. The incidence has increased in parallel with the obesity, diabetes and metabolic syndrome epidemic, thus resulting in becoming one of the main indi...
Source: Medicina Clinica - Category: General Medicine Tags: Med Clin (Barc) Source Type: research
Because of global epidemics of obesity and type 2 diabetes, the prevalence of non-alcoholic fatty liver disease (NAFLD) is increasing both in Europe and USA becoming one of the most frequent causes of chronic liver disease and predictably, one of the leading causes of liver transplantation (LT) both for end-stage liver disease and hepatocellular carcinoma. For most transplant teams around the world this will raise many challenges in terms on pre- and post-transplant management. Here we review the multifaceted impact of NAFLD on liver transplantation and will discuss: (1) NAFLD as frequent cause of cryptogenic cirrhosis, en...
Source: Journal of Hepatology - Category: Gastroenterology Authors: Tags: Review Source Type: research
I tell my patients to avoid drinking soda not just because they make you fat. Each sip of soda affects your health. Soda puts you at risk for health problems like metabolic syndrome. This is a collection of symptoms that can lead to diabetes, heart disease and other chronic diseases, like cancer. Soft drinks are the beverage of choice for millions of Americans. The latest research now reveals that sodas are a major cause of visceral fat — the deadliest kind of fat you can have, inflaming your tissues, rotting your blood vessels and upsetting your body chemistry. In a minute I’m going to tell you about a great ...
Source: Al Sears, MD Natural Remedies - Category: Complementary Medicine Authors: Tags: Heart Health heart disease metabolic syndrome Visceral Fat Source Type: news
Conclusions: As the global epidemic of obesity fuels metabolic conditions, the clinical and economic burden of NAFLD will become enormous. (Hepatology 2015)
Source: Hepatology - Category: Internal Medicine Authors: Tags: Steatohepatitis and Metabolic Liver Disease Source Type: research
Conclusions: As the global epidemic of obesity fuels metabolic conditions, the clinical and economic burden of NAFLD will become enormous.f This article is protected by copyright. All rights reserved.
Source: Hepatology - Category: Internal Medicine Authors: Tags: Steatohepatitis and Metabolic Liver Disease Source Type: research
Non-alcoholic fatty liver disease (NAFLD) is an increasingly prevalent condition paralleling the growing epidemic of obesity and type-2 diabetes. This disease shows a continuous spectrum of severity ranging from simple steatosis to overt non-alcoholic steato-hepatitis (NASH) that can further progress towards cirrhosis and hepatocarcinoma.1 Although the complete physiopathology is not fully understood, many factors such as insulin resistance, inflammation, oxidative stress and lipotoxicity are involved in the onset of NAFLD.2 3 Obstructive sleep apnoea (OSA) is independently associated with the different components of the m...
Source: Thorax - Category: Respiratory Medicine Authors: Tags: Editorial Source Type: research
More News: Alcoholism | Cirrhosis | Diabetes | Eating Disorders & Weight Management | Endocrinology | Epidemics | Epidemiology | Fatty Liver Disease (FLD) | Gastroenterology | Liver | Liver Disease | Metabolic Syndrome | Non-alcoholic Fatty Liver Diseases (NAFLD) | Obesity | Urology & Nephrology